FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806055242> ?p ?o ?g. }

• W2806055242 endingPage "1049" @default.
• W2806055242 startingPage "1049" @default.
• W2806055242 abstract "1049 Background: Compared to placebo (P) + fulvestrant (F), the MONARCH 2 HR+, HER2- ABC trial showed abemaciclib + F significantly improved PFS and ORR with a generally tolerable safety profile. Here, patient-reported HRQoL, functioning, and symptoms are reported. Methods: Study details were previously reported (Sledge et al. 2017). Data from the modified Brief Pain Inventory short form (mBPI-sf), EORTC QLQ-C30 and EORTC BR23 were collected at baseline, cycle 2 (C2), every 2 cycles from C3 - C13, and then every 3 cycles until short term follow up. Time to worsening (TTW) of pain (≥2 point increase of “worst pain” or ≥ 1 level increase of WHO analgesic class) were analyzed by Cox model. Change from baseline for EORTC QLQ-C30 and BR23 subscales and mBPI-sf were analyzed by mixed model. Differences of change from baseline (for each and across all visits) between arms were analyzed. Results: PRO completion rates were > 85% for baseline and on-treatment visits; duration of treatment was longer for abemaciclib + F patients (median 15 vs 9 cycles). The TTW for pain was similar between abemaciclib + F and P + F arms (HR = 0.900; p = .4005). No clinical and statistical significance was observed in the EORTC QLQ-C30 and BR23 function and symptom scales or the mBPI-sf; exceptions were higher diarrhea, appetite loss (AL) and nausea/vomiting (N/V) in the abemaciclib + F arm, which were consistent with reported adverse events (AE). The by-cycle analysis showed these higher mean symptom scores were transient for AL and NV, which increased in the first few cycles then gradually returned to near-baseline after cycle 7. Mean diarrhea scores returned to near-baseline levels post-therapy. Conclusions: In addition to significantly improved PFS and ORR, abemaciclib + F did not show statistically significant and clinically meaningful differences in patient-reported global health, functioning, or most symptoms compared to P + F. Increased GI-related symptoms were transient and consistent with the manageable, reversible AE profile; the highest symptom burden was reported during early visits. Clinical trial information: NCT02107703." @default.
• W2806055242 created "2018-06-13" @default.
• W2806055242 creator A5004140914 @default.
• W2806055242 creator A5005128372 @default.
• W2806055242 creator A5005424988 @default.
• W2806055242 creator A5007579054 @default.
• W2806055242 creator A5014192243 @default.
• W2806055242 creator A5017506744 @default.
• W2806055242 creator A5027475930 @default.
• W2806055242 creator A5031548464 @default.
• W2806055242 creator A5043706727 @default.
• W2806055242 creator A5066769011 @default.
• W2806055242 creator A5091245889 @default.
• W2806055242 date "2018-05-20" @default.
• W2806055242 modified "2023-09-27" @default.
• W2806055242 title "Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy." @default.
• W2806055242 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.1049" @default.
• W2806055242 hasPublicationYear "2018" @default.
• W2806055242 type Work @default.
• W2806055242 sameAs 2806055242 @default.
• W2806055242 citedByCount "7" @default.
• W2806055242 countsByYear W28060552422018 @default.
• W2806055242 countsByYear W28060552422019 @default.
• W2806055242 countsByYear W28060552422021 @default.
• W2806055242 countsByYear W28060552422022 @default.
• W2806055242 countsByYear W28060552422023 @default.
• W2806055242 crossrefType "journal-article" @default.
• W2806055242 hasAuthorship W2806055242A5004140914 @default.
• W2806055242 hasAuthorship W2806055242A5005128372 @default.
• W2806055242 hasAuthorship W2806055242A5005424988 @default.
• W2806055242 hasAuthorship W2806055242A5007579054 @default.
• W2806055242 hasAuthorship W2806055242A5014192243 @default.
• W2806055242 hasAuthorship W2806055242A5017506744 @default.
• W2806055242 hasAuthorship W2806055242A5027475930 @default.
• W2806055242 hasAuthorship W2806055242A5031548464 @default.
• W2806055242 hasAuthorship W2806055242A5043706727 @default.
• W2806055242 hasAuthorship W2806055242A5066769011 @default.
• W2806055242 hasAuthorship W2806055242A5091245889 @default.
• W2806055242 hasConcept C121608353 @default.
• W2806055242 hasConcept C126322002 @default.
• W2806055242 hasConcept C142724271 @default.
• W2806055242 hasConcept C143998085 @default.
• W2806055242 hasConcept C159110408 @default.
• W2806055242 hasConcept C197934379 @default.
• W2806055242 hasConcept C204787440 @default.
• W2806055242 hasConcept C27081682 @default.
• W2806055242 hasConcept C2779951463 @default.
• W2806055242 hasConcept C2780482068 @default.
• W2806055242 hasConcept C2780580376 @default.
• W2806055242 hasConcept C2780852908 @default.
• W2806055242 hasConcept C530470458 @default.
• W2806055242 hasConcept C65409693 @default.
• W2806055242 hasConcept C71924100 @default.
• W2806055242 hasConcept C84606932 @default.
• W2806055242 hasConceptScore W2806055242C121608353 @default.
• W2806055242 hasConceptScore W2806055242C126322002 @default.
• W2806055242 hasConceptScore W2806055242C142724271 @default.
• W2806055242 hasConceptScore W2806055242C143998085 @default.
• W2806055242 hasConceptScore W2806055242C159110408 @default.
• W2806055242 hasConceptScore W2806055242C197934379 @default.
• W2806055242 hasConceptScore W2806055242C204787440 @default.
• W2806055242 hasConceptScore W2806055242C27081682 @default.
• W2806055242 hasConceptScore W2806055242C2779951463 @default.
• W2806055242 hasConceptScore W2806055242C2780482068 @default.
• W2806055242 hasConceptScore W2806055242C2780580376 @default.
• W2806055242 hasConceptScore W2806055242C2780852908 @default.
• W2806055242 hasConceptScore W2806055242C530470458 @default.
• W2806055242 hasConceptScore W2806055242C65409693 @default.
• W2806055242 hasConceptScore W2806055242C71924100 @default.
• W2806055242 hasConceptScore W2806055242C84606932 @default.
• W2806055242 hasIssue "15_suppl" @default.
• W2806055242 hasLocation W28060552421 @default.
• W2806055242 hasOpenAccess W2806055242 @default.
• W2806055242 hasPrimaryLocation W28060552421 @default.
• W2806055242 hasRelatedWork W2117568169 @default.
• W2806055242 hasRelatedWork W2132406120 @default.
• W2806055242 hasRelatedWork W2347684256 @default.
• W2806055242 hasRelatedWork W2371976426 @default.
• W2806055242 hasRelatedWork W2383468064 @default.
• W2806055242 hasRelatedWork W2604052601 @default.
• W2806055242 hasRelatedWork W4235127086 @default.
• W2806055242 hasRelatedWork W63739596 @default.
• W2806055242 hasRelatedWork W76636966 @default.
• W2806055242 hasRelatedWork W1940111014 @default.
• W2806055242 hasVolume "36" @default.
• W2806055242 isParatext "false" @default.
• W2806055242 isRetracted "false" @default.
• W2806055242 magId "2806055242" @default.
• W2806055242 workType "article" @default.